These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15243303)

  • 1. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
    Yosefy C; Magen E; Kiselevich A; Priluk R; London D; Volchek L; Viskoper RJ
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):215-22. PubMed ID: 15243303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
    Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
    Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
    J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
    Hanefeld M; Patwardhan R; Jones NP;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):13-23. PubMed ID: 17174222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients.
    Danaoğlu Z; Kültürsay H; Kayikçioğlu M; Can L; Payzin S
    Anadolu Kardiyol Derg; 2003 Dec; 3(4):331-7. PubMed ID: 14675884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.
    Derosa G; Cicero AF; Dangelo A; Gaddi A; Ragonesi PD; Piccinni MN; Salvadeo S; Ciccarelli L; Pricolo F; Ghelfi M; Ferrari I; Montagna L; Fogari R
    Hypertens Res; 2005 Nov; 28(11):917-24. PubMed ID: 16555581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
    Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
    Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
    Lachin JM; Viberti G; Zinman B; Haffner SM; Aftring RP; Paul G; Kravitz BG; Herman WH; Holman RR; Kahn SE;
    Clin J Am Soc Nephrol; 2011 May; 6(5):1032-40. PubMed ID: 21454723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension.
    Horio T; Suzuki M; Takamisawa I; Suzuki K; Hiuge A; Yoshimasa Y; Kawano Y
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1626-30. PubMed ID: 16364837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.
    Mustaffa N; Ibrahim S; Abdullah WZ; Yusof Z
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):512-20. PubMed ID: 21537159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus.
    Pop-Busui R; Oral E; Raffel D; Byun J; Bajirovic V; Vivekanandan-Giri A; Kellogg A; Pennathur S; Stevens MJ
    Metabolism; 2009 Jul; 58(7):989-94. PubMed ID: 19394661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension.
    McGowan CL; Murai H; Millar PJ; Notarius CF; Morris BL; Floras JS
    Heart; 2013 Feb; 99(4):240-6. PubMed ID: 23257173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
    Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
    Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.
    Shargorodsky M; Wainstein J; Gavish D; Leibovitz E; Matas Z; Zimlichman R
    Am J Hypertens; 2003 Aug; 16(8):617-22. PubMed ID: 12878365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
    Mori Y; Itoh Y; Obata T; Tajima N
    Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.